Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma - Related Studies

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

This study is ongoing, but not recruiting participants.

Study NCT00098475. Last updated on July 22, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Multiple Myeloma
		Neoplasms, Plasma Cell

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

3	Interventions listed in this trial
		acetylsalicylic acid
		dexamethasone
		lenalidomide
		thalidomide

4	Additional drug interventions recognized in this trial
		Aspirin
		Dexamethasone acetate

5	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Bacterial Agents
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antiemetics
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Antirheumatic Agents
		Autonomic Agents
		Cardiovascular Agents
		Central Nervous System Agents
		Cyclooxygenase Inhibitors
		Enzyme Inhibitors
		Fibrin Modulating Agents
		Fibrinolytic Agents
		Gastrointestinal Agents
		Glucocorticoids
		Growth Inhibitors
		Growth Substances
		Hematologic Agents
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Leprostatic Agents
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Platelet Aggregation Inhibitors
		Sensory System Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)